vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Rocket Lab Corp的1.0倍（$183.1M vs $179.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -29.5%，领先42.8%），Rocket Lab Corp同比增速更快（35.7% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
AMPH vs RKLB — 直观对比
营收规模更大
AMPH
是对方的1.0倍
$179.7M
营收增速更快
RKLB
高出37.5%
-1.8%
净利率更高
AMPH
高出42.8%
-29.5%
自由现金流更多
AMPH
多$138.8M
$-114.2M
两年增速更快
RKLB
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $179.7M |
| 净利润 | $24.4M | $-52.9M |
| 毛利率 | 46.8% | 38.0% |
| 营业利润率 | 19.4% | -28.4% |
| 净利率 | 13.3% | -29.5% |
| 营收同比 | -1.8% | 35.7% |
| 净利润同比 | -35.7% | -1.1% |
| 每股收益（稀释后） | $0.51 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRKLB
| Q4 25 | $183.1M | $179.7M | ||
| Q3 25 | $191.8M | $155.1M | ||
| Q2 25 | $174.4M | $144.5M | ||
| Q1 25 | $170.5M | $122.6M | ||
| Q4 24 | $186.5M | $132.4M | ||
| Q3 24 | $191.2M | $104.8M | ||
| Q2 24 | $182.4M | $106.3M | ||
| Q1 24 | $171.8M | $92.8M |
净利润AMPHRKLB
| Q4 25 | $24.4M | $-52.9M | ||
| Q3 25 | $17.4M | $-18.3M | ||
| Q2 25 | $31.0M | $-66.4M | ||
| Q1 25 | $25.3M | $-60.6M | ||
| Q4 24 | $38.0M | $-52.3M | ||
| Q3 24 | $40.4M | $-51.9M | ||
| Q2 24 | $37.9M | $-41.6M | ||
| Q1 24 | $43.2M | $-44.3M |
毛利率AMPHRKLB
| Q4 25 | 46.8% | 38.0% | ||
| Q3 25 | 51.4% | 37.0% | ||
| Q2 25 | 49.6% | 32.1% | ||
| Q1 25 | 50.0% | 28.8% | ||
| Q4 24 | 46.5% | 27.8% | ||
| Q3 24 | 53.3% | 26.7% | ||
| Q2 24 | 52.2% | 25.6% | ||
| Q1 24 | 52.4% | 26.1% |
营业利润率AMPHRKLB
| Q4 25 | 19.4% | -28.4% | ||
| Q3 25 | 13.2% | -38.0% | ||
| Q2 25 | 24.2% | -41.3% | ||
| Q1 25 | 21.9% | -48.3% | ||
| Q4 24 | 24.2% | -38.9% | ||
| Q3 24 | 29.8% | -49.5% | ||
| Q2 24 | 30.3% | -40.7% | ||
| Q1 24 | 27.9% | -46.4% |
净利率AMPHRKLB
| Q4 25 | 13.3% | -29.5% | ||
| Q3 25 | 9.0% | -11.8% | ||
| Q2 25 | 17.8% | -46.0% | ||
| Q1 25 | 14.8% | -49.5% | ||
| Q4 24 | 20.4% | -39.5% | ||
| Q3 24 | 21.1% | -49.6% | ||
| Q2 24 | 20.8% | -39.2% | ||
| Q1 24 | 25.1% | -47.7% |
每股收益（稀释后）AMPHRKLB
| Q4 25 | $0.51 | $-0.09 | ||
| Q3 25 | $0.37 | $-0.03 | ||
| Q2 25 | $0.64 | $-0.13 | ||
| Q1 25 | $0.51 | $-0.12 | ||
| Q4 24 | $0.74 | $-0.11 | ||
| Q3 24 | $0.78 | $-0.10 | ||
| Q2 24 | $0.73 | $-0.08 | ||
| Q1 24 | $0.81 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $1.0B |
| 总债务越低越好 | $608.7M | $152.4M |
| 股东权益账面价值 | $788.8M | $1.7B |
| 总资产 | $1.6B | $2.3B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资AMPHRKLB
| Q4 25 | $282.8M | $1.0B | ||
| Q3 25 | $276.2M | $976.7M | ||
| Q2 25 | $231.8M | $688.1M | ||
| Q1 25 | $236.9M | $428.4M | ||
| Q4 24 | $221.6M | $419.0M | ||
| Q3 24 | $250.5M | $442.4M | ||
| Q2 24 | $217.8M | $496.8M | ||
| Q1 24 | $289.6M | $492.5M |
总债务AMPHRKLB
| Q4 25 | $608.7M | $152.4M | ||
| Q3 25 | $608.6M | $347.0M | ||
| Q2 25 | $607.7M | $346.5M | ||
| Q1 25 | $603.9M | $345.9M | ||
| Q4 24 | $601.6M | $345.4M | ||
| Q3 24 | $596.4M | $61.2M | ||
| Q2 24 | $586.9M | $64.2M | ||
| Q1 24 | $594.0M | $66.8M |
股东权益AMPHRKLB
| Q4 25 | $788.8M | $1.7B | ||
| Q3 25 | $776.7M | $1.3B | ||
| Q2 25 | $757.5M | $688.5M | ||
| Q1 25 | $751.3M | $431.3M | ||
| Q4 24 | $732.3M | $382.5M | ||
| Q3 24 | $727.7M | $419.8M | ||
| Q2 24 | $713.3M | $455.2M | ||
| Q1 24 | $672.4M | $478.9M |
总资产AMPHRKLB
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
负债/权益比AMPHRKLB
| Q4 25 | 0.77× | 0.09× | ||
| Q3 25 | 0.78× | 0.27× | ||
| Q2 25 | 0.80× | 0.50× | ||
| Q1 25 | 0.80× | 0.80× | ||
| Q4 24 | 0.82× | 0.90× | ||
| Q3 24 | 0.82× | 0.15× | ||
| Q2 24 | 0.82× | 0.14× | ||
| Q1 24 | 0.88× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-114.2M |
| 自由现金流率自由现金流/营收 | 13.4% | -63.6% |
| 资本支出强度资本支出/营收 | 4.5% | 27.6% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流AMPHRKLB
| Q4 25 | $32.9M | $-64.5M | ||
| Q3 25 | $52.6M | $-23.5M | ||
| Q2 25 | $35.6M | $-23.2M | ||
| Q1 25 | $35.1M | $-54.2M | ||
| Q4 24 | $29.0M | $-2.4M | ||
| Q3 24 | $60.0M | $-30.9M | ||
| Q2 24 | $69.1M | $-13.0M | ||
| Q1 24 | $55.3M | $-2.6M |
自由现金流AMPHRKLB
| Q4 25 | $24.6M | $-114.2M | ||
| Q3 25 | $47.2M | $-69.4M | ||
| Q2 25 | $25.0M | $-55.3M | ||
| Q1 25 | $24.4M | $-82.9M | ||
| Q4 24 | $16.6M | $-23.9M | ||
| Q3 24 | $46.2M | $-41.9M | ||
| Q2 24 | $63.1M | $-28.3M | ||
| Q1 24 | $46.5M | $-21.8M |
自由现金流率AMPHRKLB
| Q4 25 | 13.4% | -63.6% | ||
| Q3 25 | 24.6% | -44.8% | ||
| Q2 25 | 14.3% | -38.3% | ||
| Q1 25 | 14.3% | -67.6% | ||
| Q4 24 | 8.9% | -18.1% | ||
| Q3 24 | 24.1% | -40.0% | ||
| Q2 24 | 34.6% | -26.7% | ||
| Q1 24 | 27.1% | -23.5% |
资本支出强度AMPHRKLB
| Q4 25 | 4.5% | 27.6% | ||
| Q3 25 | 2.8% | 29.6% | ||
| Q2 25 | 6.1% | 22.2% | ||
| Q1 25 | 6.3% | 23.4% | ||
| Q4 24 | 6.7% | 16.3% | ||
| Q3 24 | 7.2% | 10.5% | ||
| Q2 24 | 3.3% | 14.4% | ||
| Q1 24 | 5.1% | 20.7% |
现金转化率AMPHRKLB
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
